Abstract
Ovarian cancer is one of the leading causes for death of women. Every year the percentage of mortality rate is increasing day by day. Various chemotherapeutic agents are used to increase the survival rate of patients with ovarian cancer, but the available conventional dosage forms/marketed preparations are associated with several limitations. The use of nanotechnology in drug delivery contributes to their small size (10–100 nm), which improves the circulation and enables superior accumulation of therapeutic drugs at the tumor sites. In future, the use of nanotechnology will enable passive targeting and further improvements can be made using targeting moieties.
Acknowledgment
The authors are thankful to Director, University Institute of Pharmacy, Pt Ravi Shankar Shukla University Raipur, Chhattisgarh for providing necessary infrastructural facilities.
Declaration of interest
The authors report no declarations of interest. The authors alone are responsible for the content and writing of the paper.
The authors are thankful to UGC-MRP F. No. 42-706/2013 (SR) and CCOST/MRP/2012 Endt. No. 1926 for providing financial assistance relating to this work.